# Butterfly Network, Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [Butterfly Network, Inc.](/companies/bfly.md) (CIK 1804176)
- Form: 10-Q
- Filed: 2023-05-11
- Accepted by EDGAR: May 11, 2023, 17:02 ET
- Period: 2023-03-31
- Accession: 0001558370-23-009428
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1804176/000155837023009428/bfly-20230331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1804176/000155837023009428/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $15.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $6.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $9.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $16.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | −$35.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $87.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | −$33.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 202,565,877 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$43.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $193.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $322.5m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $381.7m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $44.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $85.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-03-31 | $296.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,467 characters.

*The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto contained in our 2022 Annual Report on Form 10-K. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described under the caption “Risk Factors” in Item 1A of Part I of our 2022 Annual Report on Form 10-K and in Item 1A of Part II of this Quarterly Report on Form 10-Q as filed with the SEC. Actual results may differ materially from those contained in any forward-looking statements.*

### Overview

We are an innovative digital health business transforming care with hand-held, whole-body ultrasound. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional’s pocket with a unique combination of cloud-connected software and hardware technology that is easily accessed through a mobile app.

Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. Our Ultrasound-on-Chip™ makes ultrasound more accessible outside of large healthcare institutions, while our software is intended to make the product easy to use, fully integrated with the clinical workflow and accessible on a user’s smartphone, tablet and almost any hospital computer system connected to the Internet. We aim to enable the delivery of imaging information anywhere at point-of-care to drive earlier detection throughout the body and remote management of health conditions. We market and sell the Butterfly system, which includes probes, related accessories and software subscriptions, to healthcare systems, physicians and healthcare providers through a direct sales force, distributors and our eCommerce channel.

### Key Performance Measures

We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions. Our key performance measures may fluctuate over time as the adoption of our devices increases, which may shift the revenue mix more toward software and other services. The quarterly metrics may be impacted by the timing of device sales.

### Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this measure for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and the performance of our business period over period.

Units fulfilled decreased by 1,590 units, or 31.1%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022, primarily due to decreased device sales volume across all of our sales channels, including direct and distributor sales and eCommerce.

### Software and other services mix

We define software and other services mix as a percentage of our total revenue recognized in a reporting period that is based on software subscriptions and other related services, consisting primarily of our software as a service (“SaaS”) offering. We view software and other services mix as a key indicator of the profitability of our business, and thus we believe that this measure is useful to investors.

Software and other services mix increased by 13.5 percentage points, to 42.8% for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The increase was primarily due to an increase in software license revenue as compared to a decrease in product revenue. The increase in software and other services revenue is a result of increased sales of enterprise licenses for our Butterfly Blueprint software solution, increased renewals of existing software licenses, and the recognition of software and other services revenue over the term of the service period for prior-period license sales and renewals.

### Description of Certain Components of Financial Data

### Revenue

Revenue consists of revenue from the sale of products, such as medical devices and accessories, and the sale of software and related services, classified as software and other services revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and product support and maintenance (“Support”). SaaS subscriptions include licenses for teams and individuals as well as enterprise-level subscriptions. For sales of products, revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally recognized ratably over time.

Over time, as the adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward software and other services. The quarterly revenue mix may be impacted by the timing of device sales.

To date, we have invested heavily in growing adoption at large-scale healthcare systems. As we expand our healthcare system software offerings and develop relationships with larger healthcare systems, we continue to expect a higher proportion of our sales in healthcare systems compared to eCommerce.

### Cost of revenue

Cost of product revenue consists of product costs, including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period, and we expect it to fluctuate as a percentage of product revenue over time as our focus on operational efficiencies in our supply chain may be offset by increased prices of certain inventory components.

Cost of software and other services revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate an improvement in profitability and margin expansion over time as our revenue mix shifts increasingly towards software and other services. We plan to continue to invest resources to expand and further develop our SaaS and other service offerings.

### Research and development

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expenses, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services that have not reached the point of commercialization and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities.

### Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third-party logistics, fulfillment and outbound shipping costs, advertising, promotional costs, conferences and events, facilities-related expenses and information technology costs. We expect to continue to make substantial investments in our sales capabilities.

### General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, insurance, patent fees, software costs, facilities-related expenses and outside services. Outside services consist of professional services, legal fees and other professional fees.

### Other

Operating expenses classified as other are expenses which we do not consider representative of our ongoing operations. These other expenses primarily consist of employee severance and benefits costs related to our reductions in force, litigation costs, legal settlements, and other legal costs.

### Results of Operations

We operate as a single reportable segment to reflect the way our CODM reviews and assesses the performance of the business. The accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

*(in thousands)*

| ​ ​ ​ ​ Revenue: | ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2023 ​ ​ Dollars | ​ ​ ​ | ​ ​ ​ % of ​ revenue ​ | ​ ​ ​ ​ | ​ ​ 2022 ​ ​ Dollars | ​ ​ ​ | ​ ​ % of revenue | ​ ​ ​ ​ ​ |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Product | ​ | $8,848 |  | 57.2% | ​ | $11,014 |  | 70.7% | ​ |
| Software and other services | ​ | ​ 6,628 |  | 42.8 ​ | ​ | ​ 4,560 |  | 29.3 ​ | ​ |
| **Total revenue** | **​** | **​** **15,476** |  | **100.0** **​** | **​** | **​** **15,574** |  | **100.0** **​** | **​** |
| Cost of revenue: | ​ | ​ |  | ​ | ​ | ​ |  | ​ ​ | ​ |
| Product | ​ | ​ 4,349 |  | 28.1 ​ | ​ | ​ 6,149 |  | 39.5 ​ | ​ |
| Software and other services | ​ | ​ 2,038 |  | 13.2 ​ | ​ | ​ 1,083 |  | 7.0 ​ | ​ |
| **Total cost of revenue** | **​** | **​** **6,387** |  | **41.3** **​** | **​** | **​** **7,232** |  | **46.4** **​** | **​** |
| **Gross profit (loss)** | **​** | **​** **9,089** |  | **58.7** **​** | **​** | **​** **8,342** |  | **53.6** **​** | **​** |
| Operating expenses: | ​ | ​ |  | ​ | ​ | ​ |  | ​ ​ | ​ |
| Research and development | ​ | ​ 16,651 |  | 107.6 ​ | ​ | ​ 23,623 |  | 151.7 ​ | ​ |
| Sales and marketing | ​ | ​ 10,034 |  | 64.8 ​ | ​ | ​ 15,202 |  | 97.6 ​ | ​ |
| General and administrative | ​ | ​ 11,019 |  | 71.2 ​ | ​ | ​ 18,800 |  | 120.7 ​ | ​ |
| Other | ​ | ​ 6,432 | ​ | 41.6 ​ | ​ | ​ 250 | ​ | 1.6 ​ | ​ |
| **Total operating expenses** | **​** | **​** **44,136** |  | **285.2** **​** | **​** | **​** **57,875** |  | **371.6** **​** | **​** |
| **Loss from operations** | **​** | **​** **(35,047)** |  | **(226.5)** **​** | **​** | **​** **(49,533)** |  | **(318.0)** **​** | **​** |
| Interest income | ​ | ​ 1,784 |  | 11.5 ​ | ​ | ​ 10 |  | 0.1 ​ | ​ |
| Change in fair value of warrant liabilities | ​ | ​ (207) | ​ | (1.3) ​ | ​ | ​ 5,163 | ​ | 33.2 ​ | ​ |
| Other income (expense), net | ​ | ​ 17 |  | 0.1 ​ | ​ | ​ (100) |  | (0.6) ​ | ​ |
| **Loss before provision for income taxes** | **​** | **​** **(33,453)** |  | **(216.2)** **​** | **​** | **​** **(44,460)** |  | **(285.5)** **​** | **​** |
| Provision for income taxes | ​ | ​ 87 |  | 0.6 ​ | ​ | ​ 17 |  | 0.1 ​ | ​ |
| **Net loss and comprehensive loss** | **​** | **$(33,540)** |  | **(216.7)%** | **​** | **$(44,477)** |  | **(285.6)%** | **​** |

### Comparison of the three months ended March 31, 2023 and 2022

### Revenue

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ Three months ended March 31, 2023 | ​ ​ | ​ ​ 2022 | ​ ​ ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Product |  | $8,848 | ​ | $11,014 | ​ | $(2,166) | (19.7)% |
| Software and other services |  | ​ 6,628 | ​ | ​ 4,560 | ​ | ​ 2,068 | 45.4 ​ |
| ​ | ​ | $15,476 | ​ | $15,574 | ​ | $(98) | (0.6)% |

For the three months ended March 31, 2023, total revenue of $15.5 million was flat from $15.6 million for the three months ended March 31, 2022. We saw a 15% increase in our U.S. Direct sales channel revenue, led by software and other services, as well as increases in our global health business. These increases were offset by lower revenue in our eCommerce, International, and Vet sales channels.

Product revenue decreased 19.7% to $8.8 million from $11.0 million for the three months ended March 31, 2023 and 2022, respectively. Software and other services revenue increased 45.4% to $6.6 million from $4.6 million for the three months ended March 31, 2023 and 2022, respectively.

### Cost of revenue

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2023 ​ | ​ ​ ​ ​ 2022 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Product |  | $4,349 ​ | $6,149 ​ | $(1,800) | (29.3)% |
| Software and other services |  | ​ 2,038 ​ | ​ 1,083 ​ | ​ 955 | 88.2 ​ |
| ​ | ​ | $6,387 ​ | $7,232 ​ | $(845) | (11.7)% |
| Percentage of revenue | ​ | 41.3% | 46.4% |  | ​ |

Cost of product revenue decreased by $1.8 million, or 29.3%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This decrease was primarily driven by the decrease in devices sold.

Cost of software and other services revenue increased by $1.0 million, or 88.2%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This increase was primarily driven by higher amortization expenses of $0.8 million related to newly deployed internally-developed software that supports our SaaS offerings. The increase was also due to higher hosting costs and service costs in relation to the increase in software and other services revenue.

### Research and development

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2023 ​ | ​ ​ ​ ​ 2022 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development |  | $16,651 | $23,623 | $(6,972) | (29.5)% |
| Percentage of revenue | ​ | 107.6% | 151.7% |  | ​ |

Research and development expenses decreased by $7.0 million, or 29.5%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This decrease was primarily driven by lower personnel costs of $5.2 million related to our reductions in force during the third quarter of 2022 and the first quarter of 2023 as well as reductions of $1.1 million in consulting fees as we developed our internal capabilities to perform previously outsourced functions and $0.6 million in engineering and software costs related our reduced headcount.

### Sales and marketing

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2023 ​ | ​ ​ ​ ​ 2022 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Sales and marketing |  | $10,034 | $15,202 | $(5,168) | (34.0)% |
| Percentage of revenue | ​ | 64.8% | 97.6% |  | ​ |

Sales and marketing expenses decreased by $5.2 million, or 34.0%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This decrease was primarily driven by lower personnel costs of $3.6 million related to our reductions in force during the third quarter of 2022 and the first quarter of 2023 as well as reductions in marketing expenses of $1.7 million due to our strategic shift in focusing our sales efforts on healthcare systems and our tighter management of expenses.

### General and administrative

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2023 ​ | ​ ​ ​ ​ 2022 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| General and administrative |  | $11,019 | $18,800 | $(7,781) | (41.4)% |
| Percentage of revenue | ​ | 71.2% | 120.7% |  | ​ |

General and administrative expenses decreased by $7.8 million, or 41.4%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This decrease was primarily driven by lower personnel costs of $5.5 million related to our reductions in force during the third quarter of 2022 and the first quarter of 2023 as well as reductions in professional service fees of $2.4 million related to our external audit and other accounting and legal services.

### Other

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2023 ​ | ​ ​ ​ ​ 2022 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Other |  | $6,432 | $250 | $6,182 | 2,472.8% |
| Percentage of revenue | ​ | 41.6% | 1.6% |  | ​ |

Other increased by $6.2 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This increase was primarily driven by employee severance and benefits costs of $3.6 million recognized in the first quarter of 2023 due to our reduction in force and an increase in legal costs of $2.6 million due to litigation and other legal matters not representative of our ongoing operations.

### Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations, proceeds from the Business Combination and issuances of preferred stock and convertible notes. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have historically been negative as we continue to develop new products and services and expand our customer base. We expect to have negative cash flow on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect that our existing cash, cash equivalents and cash flows from operations will be sufficient to fund our operations and meet our working capital, capital expenditure and other liquidity needs for at least the next 12 months.

Our cash and cash equivalents balance as of March 31, 2023 was $193.8 million, consisting of cash on deposit and money market funds. Our future spending on capital resources may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of our spending on strategic business initiatives.

Our restricted cash balance as of March 31, 2023 was $4.6 million, consisting of $4.0 million to secure a letter of credit for one of our office leases and $0.6 million restricted by our agreement with the Gates Foundation. The $4.0 million to secure a letter of credit is expected to be maintained as a security deposit throughout the duration of the lease. The restriction on the $0.6 million from our agreement with the Gates Foundation is expected to lapse as we fulfill our obligations in the agreement.

The nature of the Company’s cash requirements has not changed significantly during the three months ended March 31, 2023. Our material cash requirements include contractual obligations with third parties for office leases and inventory supply agreements. Our fixed lease payment obligations for office leases were $39.8 million as of March 31, 2023, with $3.8 million payable within the next 12 months. Our fixed purchase obligations for inventory supply agreements were $42.4 million as of March 31, 2023, and the entire balance remaining is payable within the next 12 months. We expect to pay for approximately 35% of the amount payable within the next 12 months using vendor advances.

We had no obligations, assets or liabilities which would be considered off-balance sheet arrangements as of March 31, 2023.

### Cash flows

### Comparison of the three months ended March 31, 2023 and 2022

The following table summarizes our sources and uses of cash for the three months ended March 31, 2023 and 2022:

*(in thousands)*

| ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2023 | ​ ​ ​ ​ 2022 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(43,252) | $(54,234) |
| Net cash provided by (used in) investing activities | ​ 74,855 | ​ (4,506) |
| Net cash provided by financing activities | ​ — | ​ 550 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $31,603 | $(58,190) |

### Net cash used in operating activities

Net cash used in operating activities represents the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by historical financing activities will continue to be our primary source of funds to support operating and capital expenditure needs for the foreseeable future.

Net cash used in operating activities decreased by $11.0 million, or 20.2%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The decrease was driven by a $12.3 million decrease in net loss adjusted for certain noncash items, partially offset by a $1.3 million increase in net working capital cash usage. The decrease in net loss adjusted for certain noncash items was primarily driven by a $10.9 million decrease in net loss and the noncash adjustments for the change in fair value of warrant liabilities and stock-based compensation expense. The increase in net working capital cash usage was primarily driven by a $2.7 million increase in cash used by accrued expenses and accounts payable and a $2.6 million increase in cash used by deferred revenue, partially offset by a $2.3 million increase in provided by accounts receivable and a $2.3 million decrease in cash used by prepaid expenses.

### Net cash used in investing activities

Net cash provided by investing activities increased by $79.4 million for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The increase was primarily due to the sale of all our investments in marketable securities for $76.5 million during the three months ended March 31, 2023.

### Net cash provided by financing activities

Net cash provided by financing activities decreased by $0.6 million, or 100.0%, for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. The decrease was primarily due to there being no exercises of stock options or warrants during the three months ended March 31, 2023.

### Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, contingent asset and liabilities and related disclosures. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, and these form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our 2022 Annual Report on Form 10-K.

### Recently Adopted Accounting Pronouncements

The Company did not identify any significant recently issued accounting pronouncements that may potentially impact our financial position and results of operations.

## Market risk

As filed, 1,560 characters.

### Interest Rate Risk

We did not have any floating rate debt as of March 31, 2023. Our cash and cash equivalents are comprised primarily of bank deposits and money market accounts. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Due to the short-term nature and low risk profile of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates, including an immediate change of 100 basis points, or one percentage point. Declines in interest rates, however, would reduce future investment income.

### Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations, other than its impact on the general economy. Nonetheless, to the extent our costs are impacted by general inflationary pressures, we may not be able to fully offset such higher costs through price increases or manufacturing efficiencies. Our inability or failure to do so could harm our business, financial condition and results of operations.

### Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

## Controls and procedures

As filed, 1,980 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our CEO and CFO, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March 31, 2023.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 322 characters.

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our 2022 Annual Report on Form 10-K. There have been no material changes to the risk factors described in the 2022 Annual Report on Form 10-K.

Filed May 11, 2023.
Source: SEC EDGAR, the filing index for accession 0001558370-23-009428. Last ingested by Listed: Nov 14, 2026, 23:40 ET. No prices; not investment advice.
